Manta™ Versus Suture-based Closure After Transcatheter Aortic Valve Implantation Trial

Inclusion Criteria: * Patients undergoing elective transfemoral TAVI for severe aortic valve stenosis with any commercially-available transcatheter heart valve (THV) * Common femoral artery diameter \> 5.0mm (14 - 22F compatible) Exclusion Criteria: * Symptomatic leg ischaemia * Previous thromboendarterectomy or plastic patch of the common femoral artery * Previous implantation of a suture-based VCD less than 30 days before, or a plug-based VCD within 6 months * Unilateral or bilateral lower extremity amputation * Systemic infection or a local infection at or near the access site * Allergy to the components any of both devices (i.e. bovine materials or any other device material, including collagen and/or collagen products, polyglycolic or polylactic acid, stainless steel or nickel) * Active bleeding or bleeding diathesis including thrombocytopenia (platelet count \<50,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand disease * Patients in whom continuous oral anticoagulation therapy cannot be stopped for the peri-procedural period or patients with INR \>1.8 at the time of the procedure * Patient unable to be adequately anti-coagulated for the procedure * Morbidly obese or cachectic (BMI \>40 kg/m2 or \<20 kg/m2) * Anatomical and procedural contraindication for suture-based or Manta closure (lack of proper puncture site in the common femoral artery in terms of calcification, size, and atherosclerotic disease) * Absence of computed tomographic data of the access site before the procedure * Patient cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life threatening disease * Known pregnancy at time of randomization (in women of childbearing potential a negative pregnancy test is mandatory) * Participating in trials in which the primary endpoint includes bleeding or vascular complications